Screening for Fabry disease in male patients with end-stage renal disease in western France - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Néphrologie & Thérapeutique Année : 2021

Screening for Fabry disease in male patients with end-stage renal disease in western France

Résumé

CONTEXT: Fabry disease is a rare X-linked genetic disease due to pathogenic variants in the GLA gene. Classic Fabry disease is characterized by glycosphingolipids accumulation in all organs including the kidney, resulting in end-stage renal disease in a subset of male patients. Fabry disease should therefore be considered in the differential diagnosis of patients with unexplained end-stage renal disease. OBJECTIVE: We performed a prospective screening study in Western France to determine the prevalence of Fabry disease in a large population of dialyzed and transplanted patients. PATIENTS AND METHODS: Patients meeting the inclusion criteria (males, 18-70 years with end-stage renal disease of unknown or vascular origin) were selected from the REIN® registry and the CRISTAL® database. Screening on filter papers was performed after patient consent was obtained during either a dialysis session or a transplantation follow-up visit. RESULTS: One thousand five hundred and sixty-one end-stage renal disease male patients were screened and 819 consented (dialysis: n=242; transplant: n=577). One single patient was found with decreased alpha-galactosidase levels <25%. GLA sequencing identified the p.Phe113Leu variant in favor of an unknown superimposed kidney disease responsible for end-stage renal disease since this GLA pathogenic variant is associated with a later-onset cardiac form of Fabry disease with minimal kidney involvement. Family cascade genotyping revealed a previously undiagnosed affected brother. CONCLUSION: The prevalence of Fabry disease in end-stage renal disease patients was 0.12%, questioning the efficacy of this screening strategy with respect to the low prevalence. However, beside the benefit for the patient and his family, the increased awareness of Fabry disease among participating nephrologists may be of interest for future patients.
Fichier principal
Vignette du fichier
Vigneau et al - Screening for Fabry disease in male patients - Manuscript - Revised R1 - Final - HAL Université de Rennes.pdf (1.32 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03253737 , version 1 (15-06-2021)

Identifiants

Citer

C Vigneau, D P Germain, D Larmet, F Jabbour, M Hourmant. Screening for Fabry disease in male patients with end-stage renal disease in western France. Néphrologie & Thérapeutique, 2021, 17 (3), pp.180-184. ⟨10.1016/j.nephro.2021.03.002⟩. ⟨hal-03253737⟩
156 Consultations
106 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More